Advanced Clear Cell Renal Cell Carcinoma
Feasibility of allogeneic CAR-T in solid tumors shown in advanced kidney cancer
Sumanta K. Pal, MD, FASCO, expressed a mix of emotions.
Findings support 120 mg daily as preferred belzutifan dose for advanced clear cell RCC
NASHVILLE, Tenn. — Belzutifan exhibited efficacy at two doses for patients with advanced clear cell renal cell carcinoma, according to randomized phase 2 study results presented at International Kidney Cancer Symposium: North America.
VIDEO: Belzutifan’s ‘bench to bedside journey’ for advanced clear cell renal cell carcinoma
MADRID — In this video with Healio, Tian Zhang, MD, talked about “the bench-to-bedside journey of belzutifan” highlighted in the LITESPARK-005 study.
VIDEO: Belzutifan plus cabozantinib potential treatment for advanced renal cell carcinoma
MADRID —Tian Zhang, MD, discussed the positive results presented at ESMO Congress on use of belzutifan combined with cabozantinib for patients with advanced clear cell renal cell carcinoma.
VIDEO: Belzutifan ‘has the chance to become a new standard-of-care’
MADRID — Toni Choueiri, MD, talked with Healio about some of the new kidney cancer data “that could be practice-changing and, for sure, practice-informing” presented at ESMO Congress.